Paper Details

  1. Home
  2. Paper Details

A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease.

Author: FarbmanEric S, HauserRobert A, KlinglerMichael, LeWittPeter A, LeeAngela, OhCharles, QianJenny, RudzińskaMonika, WatersCheryl H

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

CVT-301 (Inbrija®), a levodopa inhalation powder, was well-tolerated for 12 months in patients with Parkinson's disease. The drug maintained improvement in achieving ON states and reducing daily OFF time.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: CVT-301 (Inbrija®) is a levodopa inhalation powder for on-demand treatment of OFF episodes in Parkinson's disease patients treated with carbidopa/levodopa. Safety and efficacy results of a 12-month, dose-level blinded extension study of a phase 3 trial (SPAN℠-PD) of CVT-301 are present...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.parkreldis.2020.10.029

データ提供：米国国立医学図書館（NLM）

Levodopa Inhalation: A Breath of Fresh Air for Parkinson's Disease

Navigating the challenges of Parkinson's disease is like traveling through a vast desert, where fluctuating symptoms can create a sense of uncertainty. This study, like a refreshing desert breeze, examines the safety and efficacy of levodopa inhalation powder (CVT-301, Inbrija) for managing "OFF" episodes in patients with Parkinson's disease. This innovative approach, like a new oasis in the desert, offers an alternative route to alleviating symptoms and improving quality of life.

Levodopa Inhalation: A Promise of Relief for Parkinson's Patients

This research, like a skilled desert guide, carefully assesses the safety and efficacy of levodopa inhalation powder. The study, like a well-planned expedition, followed 325 patients over 12 months, carefully monitoring their pulmonary function, dyskinesia, and other potential side effects. The researchers found that CVT-301 was generally well-tolerated, with no significant decline in pulmonary function compared to a control group. The study also found that CVT-301 effectively reduced OFF time and improved patient-reported outcomes, suggesting that this novel approach holds promise for managing Parkinson's symptoms.

A Breath of Hope for Parkinson's Disease: A New Path to Relief

This study, like a compass guiding travelers through a challenging terrain, offers a new avenue for managing Parkinson's disease. The results suggest that levodopa inhalation powder may provide a safe and effective way to manage OFF episodes, potentially improving quality of life for individuals with Parkinson's. This study serves as a valuable stepping stone for future research and development of innovative therapies for Parkinson's disease.

Dr.Camel's Conclusion

This study provides evidence for the safety and potential efficacy of levodopa inhalation powder in managing OFF episodes in Parkinson's disease. The findings suggest that this novel approach may offer a new option for patients seeking relief from fluctuating symptoms and improving their quality of life.

Date :
  1. Date Completed 2021-11-01
  2. Date Revised 2021-11-01
Further Info :

Pubmed ID

33130477

DOI: Digital Object Identifier

10.1016/j.parkreldis.2020.10.029

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.